Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

Medicine Matters oncology

National Taiwan University, Taipei City, Taiwan

James Chih-Hsin Yang received his MD in 1986 from the National Taiwan University (NTU) and completed his PhD degree at the Graduate Institute of Clinical Medicine, NTU, in 2000. His first internal medicine residency was at the NTU Hospital and, between 1992 and 1995, he undertook medical oncology fellowship training at the National Cancer Institute in Bethesda, Maryland, USA. He is currently the Director and Distinguished Professor of the Graduate Institute of Oncology at NTU, the Director of the Department of Oncology at the NTU Hospital, and Director of Development and Planning at the new NTU Cancer Center.

Dr Yang’s research focuses on lung cancer treatment and the mechanism of multidrug resistance to chemotherapy and targeted therapy. Dr Yang is a leader in lung cancer clinical studies, particularly in new drug development for lung cancer treatment. With other investigators he established EGFR TKIs as the front-line treatment for lung cancer patients with EGFR mutations (IPASS), and was the principle investigator of several studies that led to the global approval of second and third generation EGFR TKIs.

He has published more than 200 papers in peer-reviewed scientific journals, such as the New England Journal of Medicine, The Lancet Oncology and Journal of Clinical Oncology, and served on the editorial board of Annals of Oncology and Lung Cancer. He is the current associate editor of Journal of Thoracic Oncology and Nature Scientific Reports.

Dr Yang has been the recipient of many distinguished awards. He received the 2nd Kobayashi Foundation Cancer Research Award from the Asian Clinical Oncology Society in 2012, the Taiwan National Science Council award (2012–2015), the TECO award for biotechnology in 2015, and the research award from the Ministry of Science and Technology, Taiwan (2016-2018). He is currently serving on the Board of Directors for the IASLC until 2021.